MedPath

The effect of combined inhaler aromatherapy on nausea and vomiting of pregnancy

Phase 2
Conditions
ausea and vomiting of pregnancy.
Hyperemesis gravidarum, mild or unspecified, starting before the end of the 22nd week of gestation
Registration Number
IRCT2014062914324N2
Lead Sponsor
Vice chancellor for research, Birjand University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
90
Inclusion Criteria

Pregnant women who are 16 to 40 years old, with 6 to16 weeks gestation; With literacy; With Singleton pregnancy; With mild to moderate nausea with or without vomiting (based on 3-12 PUQE-24 scores); Without any antiemetic or emetic drug use in the past 24 hours; Without tobacco use; Without psychological problems and unpleasant event during last 6 months; Pregnancy without signs of molar pregnancy and threatened abortion and pyelonephritis, thyroid dysfunction and digestive diseases and any other dis¬ease with nausea and vomiting as a symptom (vomiting according to pregnant women and physician examination); With phone number; Without olfactory disorder (according to patient). Exclusion criteria: Allergy or drug intolerance during intervention; Unwillingness to continue the study; using other drugs during the study.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of fatigue. Timepoint: Before and after intervention. Method of measurement: FSS questionnaire.;Severity of nausea and vomiting of pregnancy. Timepoint: Before and during intervention. Method of measurement: PUQE-24 questionnaire.
Secondary Outcome Measures
NameTimeMethod
Side effects. Timepoint: After intervention. Method of measurement: Final questionnaire.;Satisfaction. Timepoint: After intervention. Method of measurement: Final questionnaire.
© Copyright 2025. All Rights Reserved by MedPath